Ramachandran Ambady, Jain Sunil M, Mukherjee Sagarika, Phatak Sanjeev, Pitale Shailesh, Singh Shailendra K, Agrawal Navneet, Majumdar Anirban, Deshpande Neeta, Jhulka Sandeep, Minakshisundaram Shunmugavelu, Chawla Manoj, Lodha Sailesh, Maheshwari Anuj, Makkar Brij Mohan, Rao Sadashiva, Shah Parag, Ghosh Romik, Mohanasundaram Senthilnathan, Menon Shalini, Chodankar Deepa, Kanade Vaishali, Trivedi Chirag
Department of Diabetology, Dr. Ramachandran's Diabetes Hospital, No. 28, Marshall's Road, Egmore, Chennai 600 008, India.
Department of Endocrinology, TOTALL Diabetes Hormone Institute, Indore, India.
Ther Adv Endocrinol Metab. 2020 Jun 27;11:2042018820937217. doi: 10.1177/2042018820937217. eCollection 2020.
To assess the real-world management practices of subjects with type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM) in India.
This cross-sectional study was conducted between 7 March 2016 and 15 May 2016 in India as part of the seventh wave (2016) of the International Diabetes Management Practices Study (IDMPS). Adult subjects with T1DM or T2DM visiting physicians during a 2-week recruitment period were included.
A total of 55 physicians included 539 subjects who met eligibility criteria. Of 495 subjects with T2DM, 303 were treated with oral glucose lowering drugs (OGLDs) only, 158 were treated with OGLD + insulin, and 27 received insulin only. Among 44 subjects with T1DM receiving insulin, 13 (29.5%) were also treated with OGLD therapy. The most commonly used insulin regimens were basal alone (69/184; 37.5%) and premixed alone (63/184; 34.2%) in subjects with T2DM, and basal + prandial insulin (24/44; 54.5%) in subjects with T1DM. Proportions of subjects achieving glycemic targets were low [glycated haemoglobin (HbA1c) <7%: T1DM = 7.3% (3/44), T2DM = 25.2% (106/495); as targeted by the treating physician: T1DM = 31.8% (14/44), T2DM = 32.1% (59/185); global target: T1DM = 4.8% (2/42) and T2DM = 1.7% (8/482)]. In subjects with T2DM, HbA1c <7% was noted in 11/22 subjects receiving insulin only and 76/260 receiving only OGLDs. Lack of experience in self-managing insulin dosing, poor diabetes education and failure to titrate insulin dosages were the main reasons for non-achievement of glycemic targets.
Timely insulinization, education and empowerment of people with diabetes may help improve glycemic control in India.
评估印度2型糖尿病(T2DM)和1型糖尿病(T1DM)患者的实际管理情况。
作为国际糖尿病管理实践研究(IDMPS)第七波(2016年)的一部分,于2016年3月7日至2016年5月15日在印度进行了这项横断面研究。纳入在为期2周的招募期内就诊的成年T1DM或T2DM患者。
共有55名医生纳入了539名符合资格标准的受试者。在495名T2DM患者中,303名仅接受口服降糖药(OGLD)治疗,158名接受OGLD +胰岛素治疗,27名仅接受胰岛素治疗。在44名接受胰岛素治疗的T1DM患者中,13名(29.5%)也接受了OGLD治疗。T2DM患者中最常用的胰岛素治疗方案是仅基础胰岛素(69/184;37.5%)和仅预混胰岛素(63/184;34.2%),T1DM患者中最常用的是基础+餐时胰岛素(24/44;54.5%)。达到血糖目标的受试者比例较低[糖化血红蛋白(HbA1c)<7%:T1DM = 7.3%(3/44),T2DM = 25.2%(106/495);按照治疗医生的目标:T1DM = 31.8%(14/44),T2DM = 32.1%(59/185);总体目标:T1DM = 4.8%(2/42),T2DM = 1.7%(8/482)]。在T2DM患者中,仅接受胰岛素治疗的22名受试者中有11名HbA1c<7%,仅接受OGLD治疗的260名受试者中有76名HbA1c<7%。胰岛素剂量自我管理经验不足、糖尿病教育不佳以及未调整胰岛素剂量是未达到血糖目标的主要原因。
对糖尿病患者及时进行胰岛素治疗、教育并赋予其自主权可能有助于改善印度的血糖控制。